Mol. Cells 2012; 33(3): 309-316
Published online February 28, 2012
https://doi.org/10.1007/s10059-012-2280-7
© The Korean Society for Molecular and Cellular Biology
Correspondence to : *Correspondence: kwonhj@yonsei.ac.kr
To identify specific biomarkers generated upon exposure of L5178Y mouse lymphoma cells to carcinogens, 2-DE and MALDI-TOF MS analysis were conducted using the cellular proteome of L5178Y cells that had been treated with the known carcinogens, 1,2-dibromoethane and O-nitrotoluene and the noncarcinogens, emodin and D-mannitol. Eight protein spots that showed a greater than 1.5-fold increase or decrease in intensity following carci-nogen treatment compared with treatment with noncarci-nogens were selected. Of the identified proteins, we fo-cused on the candidate biomarker ERM-binding phosphoprotein 50 (EBP50), the expression of which was specifically increased in response to treatment with the carcinogens. The expression level of EBP50 was determined by western analysis using polyclonal rabbit anti-EBP50 antibody. Further, the expression level of EBP50 was increased in cells treated with seven additional carcinogens, verifying that EBP50 could serve as a specific biomarker for carcinogens.
Keywords biomarker, carcinogen, EBP50, toxicoproteomics
Mol. Cells 2012; 33(3): 309-316
Published online March 31, 2012 https://doi.org/10.1007/s10059-012-2280-7
Copyright © The Korean Society for Molecular and Cellular Biology.
Yoen Jung Lee, In-Kwon Choi, Yhun Yhong Sheen1, Sue Nie Park2, and Ho Jeong Kwon*
Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Korea, College of pharmacy, Ewha Womans University, Seoul 120-750, Korea, 2Hazardous Substances Analysis Division at Seoul Regional FDA, Korea Food and Drug Administration, Seoul 158-050, Korea
Correspondence to:*Correspondence: kwonhj@yonsei.ac.kr
To identify specific biomarkers generated upon exposure of L5178Y mouse lymphoma cells to carcinogens, 2-DE and MALDI-TOF MS analysis were conducted using the cellular proteome of L5178Y cells that had been treated with the known carcinogens, 1,2-dibromoethane and O-nitrotoluene and the noncarcinogens, emodin and D-mannitol. Eight protein spots that showed a greater than 1.5-fold increase or decrease in intensity following carci-nogen treatment compared with treatment with noncarci-nogens were selected. Of the identified proteins, we fo-cused on the candidate biomarker ERM-binding phosphoprotein 50 (EBP50), the expression of which was specifically increased in response to treatment with the carcinogens. The expression level of EBP50 was determined by western analysis using polyclonal rabbit anti-EBP50 antibody. Further, the expression level of EBP50 was increased in cells treated with seven additional carcinogens, verifying that EBP50 could serve as a specific biomarker for carcinogens.
Keywords: biomarker, carcinogen, EBP50, toxicoproteomics
Yoen Jung Lee, In-Kwon Choi, Yhun Yhong Sheen, Sue Nie Park, and Ho Jeong Kwon*
Mol. Cells 2012; 33(2): 203-210 https://doi.org/10.1007/s10059-012-2271-8Byeonggeun Kang, Byunghee Kang, Tae-Young Roh, Rho Hyun Seong, and Won Kim
Mol. Cells 2022; 45(5): 343-352 https://doi.org/10.14348/molcells.2022.0001Jieun Lee, Youngju Kim, Seonghee Jin, Heeseung Yoo, Sumin Jeong, Euna Jeong, and Sukjoon Yoon
Mol. Cells 2021; 44(11): 843-850 https://doi.org/10.14348/molcells.2021.0169